Clinical trial · Interventional
Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients
Phase II Trial of Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients With Small Primary Tumor
NCT00891475CI-TRIAL-00013746completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate efficacy and safety of Radiofrequency ablation in metastatic renal cell carcinoma patients with primary tumor less than 5 cm before medical treatment. Ablation may allow for reduced morbidity and may increase the likelihood of patients receiving systemic therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Renal Cell | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiofrequency ablation; Interferon-alpha | Procedure | — | UNRESOLVED |
| Radiofrequency ablation; Sunitinib maleate | Procedure | — | UNRESOLVED |
| Sunitinib maleate | Drug | Sunitinib | ALIAS |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Arm 1
- description
- 38 patients
- interventionNames
- Procedure: Radiofrequency ablation; Interferon-alpha
- type
- EXPERIMENTAL
- label
- Arm 2
- description
- 38 patients
- interventionNames
- Procedure: Radiofrequency ablation; Sunitinib maleate
- type
- EXPERIMENTAL
- label
- Arm 3
- description
- 38 patients
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically proven renal cell carcinoma before RFA; * Primary tumor no grater than 5 cm; * CT-confirmed metastatic measurable sites; * Good prognosis by adapted MSKCC criteria; * No treatment for RCC;
References
Publications (0)
Data not yet available
No reference posted for this study.